Azacitidine
Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
Forma Therapeutics, Inc.Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
39 Active assets in the Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Virogin Biotech Canada Ltd | Phase 2 | BB |
Durvalumab West China Hospital | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Shanghai 6th People's Hospital | Phase 2 | BB |
Irinotecan Tianjin Medical University Cancer Institute and Hospital | Phase 3 | B |
Atezolizumab National Cancer Institute (NCI) | Phase 2 | B |
View all 50 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →